Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Antiplasmodial imidazopyridazines : structure-activity relationship studies lead to the identification of analogues with improved solubility and hERG profiles
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID
4487271
Author(s)
Cheuka, P. M.; Larence, N.; Taylor, D.; Wittlin, S.; Chibale, K.
Antiplasmodial imidazopyridazines : structure-activity relationship studies lead to the identification of analogues with improved solubility and hERG profiles
Journal
MedChemComm
Volume
9
Number
10
Pages / Article-Number
1733-1745
Abstract
3,6-Diarylated imidazopyridazines have recently been shown to possess good in vitro antiplasmodial and in vivo antimalarial activity. However, frontrunner compounds have been associated with poor solubility and a hERG (human ether-a-go-go-related gene) inhibition liability raising concerns for potential cardiotoxicity risks. Herein, we report the synthesis and structure-activity relationship studies of new imidazopyridazines aimed at improving aqueous solubility and countering hERG inhibition while maintaining antiplasmodial potency. While we identified new analogues with potent antiplasmodial activity (IC50 = 0.031 M against the NF54 drug-sensitive strain, and IC50 = 0.0246 M against the K1 multidrug resistant strain), hERG inhibition remained an issue. Excitingly, on the other hand, new analogues with a substantially improved hERG inhibition profile (IC50 = 7.83-32.3 M) with sub-micromolar antiplasmodial activity (NF54, IC50 = 0.151-0.922 M) were identified. Similarly, the introduced molecular features also resulted in analogues with moderate to high solubility (60-200 M) while also displaying sub-micromolar antiplasmodial potency (NF54, IC50 = 0.136-0.99 M).
